Rachel Vatnsdal
Stock Analyst at JP Morgan
(4.47)
# 324
Out of 5,033 analysts
65
Total ratings
63.04%
Success rate
18.48%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $63.70 | +19.31% | 4 | Aug 7, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $10 → $14 | $17.75 | -21.10% | 5 | Aug 6, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $15.13 | -7.47% | 1 | Aug 4, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $32.16 | -3.61% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $13.05 | -31.03% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $32.21 | +2.45% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $157.67 | +20.50% | 6 | Apr 29, 2025 | |
| RVTY Revvity | Maintains: Neutral | $120 → $100 | $95.20 | +5.05% | 4 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $20.09 | -5.43% | 4 | Mar 6, 2025 | |
| WAT Waters | Maintains: Neutral | $380 → $390 | $344.37 | +13.25% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $94.04 | -41.51% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $69.80 | -21.20% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $144.13 | +11.01% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $544.07 | +23.15% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $7.96 | +151.26% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,358.70 | +3.04% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.98 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $38.14 | +135.97% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $209.76 | +28.72% | 4 | Dec 20, 2023 |
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $63.70
Upside: +19.31%
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Overweight
Price Target: $10 → $14
Current: $17.75
Upside: -21.10%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $15.13
Upside: -7.47%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $32.16
Upside: -3.61%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $13.05
Upside: -31.03%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $32.21
Upside: +2.45%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $157.67
Upside: +20.50%
Revvity
Apr 29, 2025
Maintains: Neutral
Price Target: $120 → $100
Current: $95.20
Upside: +5.05%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $20.09
Upside: -5.43%
Waters
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $344.37
Upside: +13.25%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $94.04
Upside: -41.51%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $69.80
Upside: -21.20%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $144.13
Upside: +11.01%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $544.07
Upside: +23.15%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $7.96
Upside: +151.26%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,358.70
Upside: +3.04%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.98
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $38.14
Upside: +135.97%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $209.76
Upside: +28.72%